Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development-Reference-Cited by-同舟云学术

Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development

Published:2009-05-13 Issue:2 Volume:86 Page:167-174
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Wang Y,Sung C,Dartois C,Ramchandani R,Booth B P,Rock E,Gobburu J

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference24 articles.

1. Can the pharmaceutical industry reduce attrition rates?

2. Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung Cancer

3. End Points and United States Food and Drug Administration Approval of Oncology Drugs

4. Accelerated Approval of Oncology Products: A Decade of Experience

Cited by 193 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the prognosis in patients with small-cell lung cancer treated by chemotherapy using tumor shrinkage rate-based radiomics;European Journal of Medical Research;2024-08-02

2. Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer;European Journal of Cancer;2024-08

3. Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice;Journal of Pharmacokinetics and Pharmacodynamics;2024-06-21

4. Bridging the gap between two‐stage and joint models: The case of tumor growth inhibition and overall survival models;Statistics in Medicine;2024-06-03

5. Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC);CPT: Pharmacometrics & Systems Pharmacology;2024-03-26